Change in Bone Mineral Density Clinical Trial
Official title:
The Effect of Glitazone Treatment on Bone Marrow and Bone Marrow Cells
Osteoporosis is a generalised bone disease leading to an increased risk of fractures. The
disease is caused partly by environmental and partly by genetic factors. It is well known
that the fat content of the bone marrow is increased in osteoporotic patients. Animal
studies suggest that stimulation of bone marrow stem cells through the molecule PPARgamma
with the drug rosiglitazone converts the stem cells to fat cells instead of bone cells
thereby decreasing bone strength. In a single study healthy volunteers were treated with
rosiglitazone for 14 weeks and had a decrease in bone mineral density.
In the present study we wish to investigate the effect of this treatment on bone and fat
tissue. 25 women above the age of 60 will be treated with rosiglitazone 8 mg/day for 14
weeks and compared with 25 women receiving placebo.
The effect will be evaluated as follows:
1. The effect on bone marrow density will be examined by a bone scan prior to and after
treatment and again after 6 and 9 months.
2. The effect on bone turnover will be measured in blood- and urine samples at the same
times.
3. The effect on fat distribution will be evaluated by an MRI scan after treatment.
4. The effect on bone marrow cells will be investigated bone marrow sampling immediately
after treatment
5. The direct effect on fat will be examined by a biopsy immediately after treatment The
study hypothesis is that rosiglitazone treatment decreases bone mineral density and
increases bone marrow fat content. The causal molecular mechanisms will be investigated
from the bone marrow and fat samples
n/a
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05303636 -
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
|
Phase 4 | |
| Active, not recruiting |
NCT05461573 -
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
|
Phase 3 |